Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: A prospective phase II study: The experience of Rambam and Lin Medical Centers 1996-2000

Eliahu Gez, Raphael Rubinov, Diana Gaitini, Shimon Meretyk, Lael Anson Best, Ofer Native, Avi Stein, Nahum Erlich, Alexander Beny, Jamal Zidan, Nissim Haim, Abraham Kuten

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. The current study evaluated the efficacy and toxicity of interleukin-2 (IL-2), interferon-α (IFN-α), 5-fluorouracil (5-FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). METHODS. Sixty-two MRCC patients, median age 63 years, received immunochemotherapy. Eastern Cooperative Oncology Group performance status was 1 for 45 patients and 2 for 17 patients. Fifty-four patients underwent nephrectomy prior to treatment. Sites of disease were lungs, lymph nodes, bone, kidney, and liver. Treatment consisted of IL-2 10 MIU/m2 subcutaneous (SC), three times per week, Weeks 1-4; IFN-α 6 MIU/m2 SC, once per week, Weeks 1-4 and 9 MIU/m2, three times per week, Weeks 5-7; 5-FU 600 mg/m2 and VBL 6 mg/m2, intravenous bolus, Day 1 of Weeks 5 and 7. RESULTS. In a median followup of 34 months, 62 patients were evaluated for tumor response. Four patients achieved complete response for 26+, 34+, 51+, and 56+ months, respectively; 14 patients achieved partial response for a median of 14 months; and 20 patients achieved stable disease for a median of 9 months. Seven patients (5 partial response, 2 stable disease) underwent complete resection of residual tumor. Five patients remained alive with no evidence of disease for 27, 32, 36, 42, and 48 months, respectively. Nine patients achieved long-term complete response for a median of 36 months. Three-year survival rate for the entire group and for 11 complete responders was 88%. Common side effects were flu-like symptoms, nausea, headache, and depression. Four patients were excluded because of treatment intolerance, and one patient died after nephrectomy. CONCLUSIONS. Immunochemotherapy is effective and well-tolerated by patients with MRCC. Surgical intervention for resection of residual disease is justified.

Original languageEnglish
Pages (from-to)1644-1649
Number of pages6
JournalCancer
Volume95
Issue number8
DOIs
StatePublished - 15 Oct 2002
Externally publishedYes

Keywords

  • 5-fluorouracil
  • Immunochemotherapy
  • Interferon-α
  • Interleukin-2
  • Metastatic renal cell carcinoma
  • Vinblastine

Fingerprint

Dive into the research topics of 'Interleukin-2, interferon-α, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: A prospective phase II study: The experience of Rambam and Lin Medical Centers 1996-2000'. Together they form a unique fingerprint.

Cite this